Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

Inclusion Criteria

• •1\. The first cohort will include a total of 4 patients ages 12 to 17. After all tests indicate treatment safety, the second cohort will be recruited and will include patients ages 8 to 17.Patient is in immune-suppressed status by one of the following:
• •1. Primary immunodeficiency, which may include but is not limited to the following:
• •1. Chronic Granulomatous Disease (CGD)
• •2. Common Variable Immunodeficiency (CVID)
• •3. DiGeorge Syndrome (DGS)
• •4. Selective IgA Deficiency
• •5. Severe Combined Immunodeficiency (SCID)
• •6. X-Linked Agammaglobulinemia (XLA)
• •2. Pharmacologic immune-suppressed status from medications including but not limited to:
• •1. prednisone
• •2. cyclosporine
• •3. azathioprine
• •4. tacrolimus/ FK506
• •5. mycophenolate mofetil
• •6. sirolimus
• •2\. Patient has history of clinically-significant warts that are either refractory to standard therapy or for which standard therapy is contra-indicated or unreasonable 3. Patient has a total wart burden of at least 1cm 4. Patients must have tried and failed at least 2 other conventional treatments for cutaneous warts, including but not limited to:
• •* cryotherapy
• •* topical salicylic acid
• •* imiquimod
• •* topical 5FU
• •* pulsed dye laser therapy
• •* sinecatechins
• •* tretinoin or other topical retinoid
• •* intralesional candida injection
• •* bleomycin
• •* electrocautery
• •* topical cidofovir cream or gel
• •There will be a one month washout period for all treatment modalities, with the exception of intralesional candida, which will be 3 months.
• •5\. Patient desires ongoing treatment of their warts 6. Patient and/or their parent/guardian consents to participating in this study